MF

MiraeAsset Financial Group

Asia, Seoul-t'ukpyolsi, South Korea, Seoul

Description

MiraeAsset Financial Group is an investment firm.

Investor Profile

MiraeAsset Financial Group has made 6 investments, with 1 in the past 12 months and 17% as lead.

Stage Focus

  • Series C (50%)
  • Series B (50%)

Country Focus

  • United States (50%)
  • China (33%)
  • Germany (17%)

Industry Focus

  • Biotechnology
  • Life Science
  • Genetics
  • Biopharma
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Information Technology
  • Medical
  • Software
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does MiraeAsset Financial Group frequently co-invest with?

Co-Investments: 1
DC
North America, Arizona, United States, Scottsdale
Co-Investments: 1
Casdin Capital
North America, New York, United States, New York
Co-Investments: 2
Biotechnology Value Fund
North America, California, United States, San Francisco
Co-Investments: 2
Innolink Fund
Asia, Beijing, China, Haidian
Co-Investments: 1
5Y Capital
Asia, Shanghai, China, Xuhui
Co-Investments: 1
Octagon Capital Advisors
North America, New York, United States, New York
Co-Investments: 2
IMO Ventures
North America, California, United States, San Mateo
Co-Investments: 1
Chimera Investment
Asia, Abu Dhabi, United Arab Emirates, Abu Dhabi
Co-Investments: 1
Invus
North America, New York, United States, New York
Co-Investments: 2

Which angels does MiraeAsset Financial Group often collaborate with?

Adrian Cheng
Asia, Hong Kong
Shared Deals: 1

What are some of recent deals done by MiraeAsset Financial Group?

Atalanta Therapeutics

Boston, Massachusetts, United States

Atalanta Therapeutics is a biotechnology company pioneering new treatment options for neurodegenerative diseases.

BiotechnologyHealth CareLife Science
Series BJan 28, 2025
Amount Raised: $97,000,000
Septerna

San Francisco, California, United States

Septerna is a biotech firm unlocking diverse drug discovery potential in G protein-coupled receptors across various diseases.

BiotechnologyInformation TechnologyMedicalSoftware
Series BJul 11, 2023
Amount Raised: $150,000,000
Abogen Biosciences

Suzhou, Jiangsu, China

Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based RNA and DNA therapeutics.

BiotechnologyGeneticsLife Science
Series CNov 29, 2021
Amount Raised: $300,000,000
EpimAb Biotherapeutics

Shanghai, Shanghai, China

EpimAb Biotherapeutics is a privately owned biopharmaceutical R&D company.

BiopharmaBiotechnologyHealth CareTherapeutics
Series CMar 22, 2021
Amount Raised: $120,000,000
4D Molecular Therapeutics

Emeryville, California, United States

4D Molecular Therapeutics designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.

BiotechnologyGenetics
Series CJun 16, 2020
Amount Raised: $75,000,000
BioNTech

Mainz, Rheinland-Pfalz, Germany

BioNTech is a biopharmaceutical company that develops cancer therapeutics for infectious diseases.

BiopharmaBiotechnologyLife SciencePharmaceutical
Series BJul 9, 2019
Amount Raised: $325,000,000